this drug is used as a spasmolytic in pictures that occur with spasms of the smooth muscles of the gastrointestinal, biliary and urinary tract.
BUTYLHIOSCINE (butyl-scopolamine, butyl-scopolamine bromide, N-butyl-hyoscine) is a quaternary ammonium compound, a semisynthetic derivative of scopolamine. Its generic name is Butylhyoscine Bromide.
Pharmacokinetics and Pharmacodynamics
Butylhioscin develops its mechanism of action through competitive parasympathetic antagonism at the visceral neuromuscular receptors; thus producing a relaxation of the smooth muscle of the gastrointestinal, biliary and genitourinary tracts. In this way, it relieves colicky pain generated in these organs . It is widely distributed in gastrointestinal tissue, liver and kidney . It has minimal passage through the blood-brain barrier and into the eye . It is partially metabolized in the liver by enzymatic hydrolysis and is eliminated via the biliary and urinary routes.
Caution should be exercised in pregnancy , lactation, as well as in geriatric and pediatric patients. It may potentiate the action of anticholinergic drugs such as antidepressants tricyclic, quinidine, antihistamines and disopi-Ramida ; or with beta-adrenergic agonist drugs. Dopamine antagonists can antagonize the effects of BUTYLHIOSCIN. Caution should be exercised when administered in patients with intestinal atony, paralytic ileus, ulcerative colitis, heart disease, xerostomia, gastroesophageal reflux, fever, or prostatic hypertrophy.
Restrictions on use during pregnancy and lactation
It should not be used during the first trimester of pregnancy. Its use during the final 2 trimesters of pregnancy should be widely valued. It is unknown whether it is excreted in human milk.
Secondary and Adverse Reactions
Cardiovascular : BUTYLHIOSCINE can induce hypotension, tachycardia, and, rarely, shock associated with allergic reactions. Central nervous system: May cause vertigo, drowsiness, disorientation, mydriasis, dry mouth, and Cheyne-Stokes breathing. Metabolic : Inhibition of sweating and saliva secretion have been reported in people receiving BUTYLHIOSCINE. Gastrointestinal: Inhibition of salivation, decreased esophageal transit, inhibition of pancreatic trypsin and amylase production, and increased bicarbonate secretion may occur. Genitourinary : The administration of BUTYLHIOSCINE can cause difficulty in urinating. Respiratory: With the use of BUTYLHIOSCINE, cases of shortness of breath and nasal flaring have been reported. Skin : In patients receiving BUTILHIOSCINA, cases of urticaria, angioneurotic edema, rashes and other data associated with allergies have been observed. Eye : There may be cycloplegia, mydriasis , blurred vision, anisocoria, glaucoma and ocular pigmentation during the use of BUTILHIOSCINA. Other reactions: Allergies and idiosyncratic reactions are the most frequent with the use of BUTYLHIOSCINE.